The effect of intravenous pamidronate treatment for type i osteogenesis imperfecta patients have on their bone mineral density, fracture rate, and mobility

ÖZTEMÜR Z., ÖZTÜRK H., Circi E., BULUT O., ÜNER S., ALTUN A., ...Daha Fazla

HEALTHMED, cilt.6, sa.10, ss.3425-3429, 2012 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 6 Sayı: 10
  • Basım Tarihi: 2012
  • Dergi Adı: HEALTHMED
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, Veterinary Science Database
  • Sayfa Sayıları: ss.3425-3429
  • Anahtar Kelimeler: Osteogenesis imperfecta, pamidronate, bone density, CHILDREN, ALENDRONATE, NERIDRONATE, CHILDHOOD
  • Sivas Cumhuriyet Üniversitesi Adresli: Evet

Özet

Objective: Osteogenesis imperfecta (OI) is a genetic disorder caused by the mutation in encoding collagen type I, and characterised by fragile bone and reduced bone mineral density. The purpose of this study was to analyse the effects siklik intravenous pamidronate treatment has on the bone mineral density and the fracture rateand mobility.